Top lawmakers on the U.S. Senate Special Committee on Aging are turning up the heat on the nation’s largest pharmacy chains, demanding more transparency regarding where prescription drugs and their ingredients actually come from.
Chairman Rick Scott and Ranking Member Kirsten Gillibrand sent formal inquiries Wednesday to the CEOs of CVS, Walgreens, and Walmart. The letters follow up on a long-standing investigation into the safety and reliability of the American drug supply chain, specifically focusing on the country of origin for generic medications and active pharmaceutical ingredients (APIs).
The move comes on the heels of the January 29 introduction of the CLEAR LABELS Act. If passed, the bill would legally require drug labels to identify the original manufacturers of both the finished pills and the raw ingredients used to make them.
While the committee thanked CVS and Walgreens for previously expressing intent to implement such labeling, they are now pushing for specific timelines and protocols.
“As chairman and ranking member of the U.S. Senate Special Committee on Aging, we are dedicated to ensuring that every American patient has access to safe, affordable, and effective pharmaceuticals,” the senators wrote in the joint letter. “Delivering on this starts by ensuring we have transparency and accountability from foreign drug entities for American patients.”
The committee is asking the retail giants for detailed answers by March 15, 2026. Specifically, the senators want to know:
- How and when country-of-origin labeling will be rolled out.
- Whether this information will be clearly available to both pharmacists and patients in paper and online formats.
- How the companies handle drugs that are currently exempted from Food and Drug Administration (FDA) import bans.
- How the pharmacies prioritize their purchasing when a drug’s origin is known.
This latest inquiry is part of a broader push by the committee to address the United States’ heavy reliance on foreign-manufactured generics. Since late 2025, Scott and Gillibrand have sent similar warnings to pharmaceutical distributors, group purchasing organizations, and federal officials, including Secretary Pete Hegseth and Secretary Robert F. Kennedy, Jr.
The senators emphasized that because pharmacies are the “final point of care” for most Americans, their role in vetting the safety of the global supply chain is vital.
“Transparency in supply chains and product labeling is critical to ensuring a healthy market and to promoting quality products,” the letter concluded.
READ: Texas Rep. Crockett Set To Be Unemployed As Her Bid For Promotion Goes Down In Flames
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox
